WALTHAM, Mass. (AP) _ AMAG Pharmaceuticals Inc. (AMAG) on Wednesday reported a loss of $199.9 million in its fourth quarter.

On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of $5.89. Losses, adjusted for asset impairment costs and amortization costs, came to 35 cents per share.

The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 34 cents per share.

The specialty drugmaker posted revenue of $89.7 million in the period, beating Street forecasts. Five analysts surveyed by Zacks expected $88.3 million.

For the year, the company reported that its loss widened to $466.5 million, or $13.71 per share. Revenue was reported as $327.8 million.

AMAG Pharmaceuticals expects full-year revenue in the range of $230 million to $280 million.

AMAG Pharmaceuticals shares have decreased 33% since the beginning of the year. The stock has dropped 46% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AMAG at https://www.zacks.com/ap/AMAG

Automated Insights, source Associated Press News